Under the fourth amendment to the agreement, Marina issued warrants for 1,035,715 shares of common stock, which have an exercise price of $0.28 per share, subject to adjustment...The reverse stock split and the decrease in the number of authorized shares of common stock were authorized by Somaxon's stockholders at a special meeting held last week

Athersys Inc., of Cleveland, filed an S-1 with the SEC seeking to raise up to $25.6 million from the sale of 17 million shares of common stock

2 Pluristem's units each consist of one share of common stock and one warrant to purchase 0.35 of a share

Each share is convertible at the option of the holder, at any time, into about 714 shares of common stock at a conversion price of $1.40 per share, for a total of about 42.9 million shares of common stock

plans to offer 13.7 million shares of common stock at $9.50 per share

One of the drivers of the increase in value was the company's second-quarter earnings that beat analyst expectations. (See BioWorld Today, Aug. 8, 2012.) The other public financing of note was Idenix Pharmaceuticals Inc., which priced 25.3 million shares, which included 3.3 million additional shares covering overallotments, of common stock at $8 each for gross proceeds of $202.4 million...Durata Therapeutics Inc., of Morristown, N.J., priced its IPO of 7.5 million shares of common stock at a price

Details Date Achillion Pharmaceuticals Inc. (New Haven, Conn.) Private placement of stock 6.4S $41.8 Achillion raised $41.8M through the placement of common stock with QVT Financial LB 9/4/12 Advanced Cell Technology Inc. (Marlborough, Mass.) Private placement of common stock N/A $0.8 Advanced Cell entered the $35M common stock purchase agreement with Lincoln Park Capital Fund LLC, with an initial purchase of $800,000 in common stock for 8 cents per share

One of the drivers of the increase in value was the company's second-quarter earnings that beat analyst expectations. (See BioWorld Today, Aug. 8, 2012.) The other public financing of note was Idenix Pharmaceuticals Inc., which priced 25.3 million shares, which included 3.3 million additional shares covering overallotments, of common stock at $8 each for gross proceeds of $202.4 million...Durata Therapeutics Inc., of Morristown, N.J., priced its initial public offering of 7.5 million shares of

Lpath Inc., of San Diego, disclosed a 1-for-7 reverse split of the company's issued and outstanding Class A common stock and a corresponding decrease in the number of its authorized shares

Shareholders will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events, but the preferred shares will confer no voting rights on general corporate matters

The pharma agreed to purchase an additional $25 million of common stock in a separate private placement concurrent with the completion of the offering, at a price equal to the IPO price. (See BioWorld Today, Aug. 16, 2012.) The S-1/A indicated the AstraZeneca transaction translated into 6.3 million shares...Regulus reported 34.1 million shares of common stock outstanding following the offering and private placement

Common stock outstanding after the offering will be 85,280,137 shares...The notes are convertible to common stock at a rate of 1,333 shares per $1,000 principal

12 from its chairman and CEO, Jing Lou, and CPEChina Fund LP to acquire all of the outstanding shares of the company's common stock not currently owned by Lou and his affiliates

12 from its chairman and CEO, Jing Lou, and CPEChina Fund LP to acquire all of the outstanding shares of the company's common stock not currently owned by Lou and his affiliates. (See BioWorld Today, Sept. 19, 2012

has priced a $26 million direct public offering of approximately 6.3 million shares of its common stock at a price of $4.07 per share to certain affiliates of Ayer Capital, RA Capital and Quaker Partners...The company also expects to offer for sale up to an additional $2 million of shares of its common stock to an investor, which is expected to close on or before Oct. 31

common stock

Under the deal, Santarus paid an up-front cash fee of $2.5 million and committed to issue Cosmo 6 million shares of Santarus common stock, valued at around $12 million, plus $9 million in clinical and regulatory milestones for initial clinical indications, up to $6 million in clinical and regulatory milestones for a second indication for rifamycin and up to $57.5 million in commercial milestones. (See BioWorld Today, Dec. 16, 2008.) Uceris comprises a steroid drug, budesonide, combined with the

CorMedix Inc., of Bridgewater, N.J., made an initial closing of a private placement of $3 million in stock units consisting of a one-year $1,000 aggregate principal amount 9 pecent senior convertible note at 35 cents per note and a five-year warrant to purchase 2,500 shares of common stock...Each $2 unit of securities holds 1/1,000th of a share of Series A preferred stock and a warrant to purchase one share of common stock

The sheet provides for Melmed to make an equity investment of $2 million in Uluru at 40 cents per share for 5 million shares of common stock, and warrants to purchase 3 million shares at 60 cents for a term of one year